Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Advertisement

Experimental & Molecular Medicine
  • View all journals
  • Search
  • My Account Login
  • Content Explore content
  • About the journal
  • Publish with us
  • Sign up for alerts
  • RSS feed
  1. nature
  2. experimental & molecular medicine
  3. articles
  4. article
Dysferlin in a hyperCKaemic patient with caveolin 3 mutation and in C2C12 cells after p38 MAP kinase inhibition
Download PDF
Download PDF
  • Article
  • Open access
  • Published: 01 December 2003

Dysferlin in a hyperCKaemic patient with caveolin 3 mutation and in C2C12 cells after p38 MAP kinase inhibition

  • Cristina Capanni1,
  • Patrizia Sabatelli,
  • Elisabetta Mattioli,
  • Andrea Ognibene,
  • Marta Columbaro,
  • Giovanna Lattanzi,
  • Luciano Merlini,
  • Carlo Minetti,
  • Nadir M Maraldi &
  • …
  • Stefano Squarzoni 

Experimental & Molecular Medicine volume 35, pages 538–544 (2003)Cite this article

  • 1431 Accesses

  • 26 Citations

  • 3 Altmetric

  • Metrics details

Abstract

Dysferlin is a plasma membrane protein of skeletal muscle whose deficiency causes Miyoshi myopathy, limb girdle muscular dystrophy 2B and distal anterior compartment myopathy. Recent studies have reported that dysferlin is implicated in membrane repair mechanism and coimmunoprecipitates with caveolin 3 in human skeletal muscle. Caveolin 3 is a principal structural protein of caveolae membrane domains in striated muscle cells and cardiac myocytes. Mutations of caveolin 3 gene (CAV3) cause different diseases and where caveolin 3 expression is defective, dysferlin localization is abnormal. We describe the alteration of dysferlin expression and localization in skeletal muscle from a patient with raised serum creatine kinase (hyperCKaemia), whose reduction of caveolin 3 is caused by a CAV3 P28L mutation. Moreover, we performed a study on dysferlin interaction with caveolin 3 in C2C12 cells. We show the association of dysferlin to cellular membrane of C2C12 myotubes and the low affinity link between dysferlin and caveolin 3 by immunoprecipitation techniques. We also reproduced caveolinopathy conditions in C2C12 cells by a selective p38 MAP kinase inhibition with SB203580, which blocks the expression of caveolin 3. In this model, myoblasts do not fuse into myotubes and we found that dysferlin expression is reduced. These results underline the importance of dysferlin-caveolin 3 relationship for skeletal muscle integrity and propose a cellular model to clarify the dysferlin alteration mechanisms in caveolinopathies.

Similar content being viewed by others

Loss of dysferlin or myoferlin results in differential defects in excitation–contraction coupling in mouse skeletal muscle

Article Open access 05 August 2021

Cryo-EM structures of the membrane repair protein dysferlin

Article Open access 07 November 2024

Impaired myogenesis in limb girdle muscular dystrophy type 2B

Article Open access 30 September 2025

Article PDF

Author information

Authors and Affiliations

  1. Lab. Biologia Cellulare e Microscopia Elettronica IOR, Bologna, Italy

    Cristina Capanni

Authors
  1. Cristina Capanni
    View author publications

    Search author on:PubMed Google Scholar

  2. Patrizia Sabatelli
    View author publications

    Search author on:PubMed Google Scholar

  3. Elisabetta Mattioli
    View author publications

    Search author on:PubMed Google Scholar

  4. Andrea Ognibene
    View author publications

    Search author on:PubMed Google Scholar

  5. Marta Columbaro
    View author publications

    Search author on:PubMed Google Scholar

  6. Giovanna Lattanzi
    View author publications

    Search author on:PubMed Google Scholar

  7. Luciano Merlini
    View author publications

    Search author on:PubMed Google Scholar

  8. Carlo Minetti
    View author publications

    Search author on:PubMed Google Scholar

  9. Nadir M Maraldi
    View author publications

    Search author on:PubMed Google Scholar

  10. Stefano Squarzoni
    View author publications

    Search author on:PubMed Google Scholar

Rights and permissions

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Reprints and permissions

About this article

Cite this article

Capanni, C., Sabatelli, P., Mattioli, E. et al. Dysferlin in a hyperCKaemic patient with caveolin 3 mutation and in C2C12 cells after p38 MAP kinase inhibition. Exp Mol Med 35, 538–544 (2003). https://doi.org/10.1038/emm.2003.70

Download citation

  • Published: 01 December 2003

  • Issue date: 01 December 2003

  • DOI: https://doi.org/10.1038/emm.2003.70

Share this article

Anyone you share the following link with will be able to read this content:

Sorry, a shareable link is not currently available for this article.

Provided by the Springer Nature SharedIt content-sharing initiative

Keywords

  • caveolin
  • C2C12
  • dysferlin
  • membranes fusion
  • muscular dystrophy
  • p38 MAP kinase

This article is cited by

  • Loss of dysferlin or myoferlin results in differential defects in excitation–contraction coupling in mouse skeletal muscle

    • David Y. Barefield
    • Jordan J. Sell
    • Alexis R. Demonbreun

    Scientific Reports (2021)

  • Klinik und Genetik der Gliedergürteldystrophien

    • J. Finsterer

    Der Nervenarzt (2004)

Download PDF

Advertisement

Explore content

  • Research articles
  • Reviews & Analysis
  • News & Comment
  • Current issue
  • Collections
  • Sign up for alerts
  • RSS feed

About the journal

  • Special Feature
  • Journal Information
  • About the Editors
  • About the Partner
  • Contact
  • For Advertisers
  • Press Releases
  • Open Access Fees and Funding

Publish with us

  • For Authors & Referees
  • Language editing services
  • Submit manuscript

Search

Advanced search

Quick links

  • Explore articles by subject
  • Find a job
  • Guide to authors
  • Editorial policies

Experimental & Molecular Medicine (Exp Mol Med)

ISSN 2092-6413 (online)

ISSN 1226-3613 (print)

nature.com sitemap

About Nature Portfolio

  • About us
  • Press releases
  • Press office
  • Contact us

Discover content

  • Journals A-Z
  • Articles by subject
  • protocols.io
  • Nature Index

Publishing policies

  • Nature portfolio policies
  • Open access

Author & Researcher services

  • Reprints & permissions
  • Research data
  • Language editing
  • Scientific editing
  • Nature Masterclasses
  • Research Solutions

Libraries & institutions

  • Librarian service & tools
  • Librarian portal
  • Open research
  • Recommend to library

Advertising & partnerships

  • Advertising
  • Partnerships & Services
  • Media kits
  • Branded content

Professional development

  • Nature Awards
  • Nature Careers
  • Nature Conferences

Regional websites

  • Nature Africa
  • Nature China
  • Nature India
  • Nature Japan
  • Nature Middle East
  • Privacy Policy
  • Use of cookies
  • Legal notice
  • Accessibility statement
  • Terms & Conditions
  • Your US state privacy rights
Springer Nature

© 2025 Springer Nature Limited